GE, Neuroimage collaborate on neuroimaging for drug research
GE Healthcare has entered into a collaborative relationship through its medical diagnostics business, Imanet, and Neuroimage that focuses on neuroimaging and biomarker technologies in support of research clinical trials and preclinical studies.
The Imanet network of PET imaging sites provides assistance in PET imaging-based clinical trials from proof-of-concept radiochemistry to clinical imaging and the Toronto-based Neuroimage is a brain imaging contract research organization, GE said.
The companies' collaboration will provide technologies across imaging modalities for pre-clinical and clinical central nervous system, in conjunction with biomarkers for pharmacokinetics, patient selection and treatment monitoring, according to GE.
The Imanet network of PET imaging sites provides assistance in PET imaging-based clinical trials from proof-of-concept radiochemistry to clinical imaging and the Toronto-based Neuroimage is a brain imaging contract research organization, GE said.
The companies' collaboration will provide technologies across imaging modalities for pre-clinical and clinical central nervous system, in conjunction with biomarkers for pharmacokinetics, patient selection and treatment monitoring, according to GE.